Brenig Therapeutics to Present AI Designed NLRP3 Inhibitor at Keystone Symposia

Brenig Therapeutics will present new data on its brain-penetrant NLRP3 inhibitor program at the Keystone Symposia meeting, Neuroinflammation in Health and Disease, announced in a press release. The presentation, by Alexei Pushechnikov, PhD, will describe how the company used its Hybrid AI Platform to design BT-409, a small molecule targeting neuroinflammation in Parkinson's disease.

The Hybrid AI Platform combines physics-based structural biology with machine learning to optimize drug properties such as potency, selectivity, safety, and brain exposure in parallel. This approach aims to overcome challenges in developing therapies that can cross the blood-brain barrier while maintaining high target selectivity.

BT-409, discovered at Mwyngil Therapeutics and later acquired by Brenig, is now in early clinical studies. The company uses the same AI platform for its second clinical program, BT-267, a selective LRRK2 inhibitor for Parkinson's disease. Both programs demonstrate Brenig's method for designing small molecules with balanced pharmacologic profiles for central nervous system disorders.